Rapa Therapeutics LLC

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Rapamycin-resistant autologous T-cell therapyCell therapy
Non-Small Cell Lung CancerMultiple Myeloma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
March 2029 (1)
RAPA-201Phase 2Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV
Est. primary completion 2029-03-01 · NCT06708455 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.